Cambridge-based Mogrify raises additional €14.5 million to advance its mission to transform the development of life-saving cell therapies

Cambridge-based biotech company Mogrify has raised €14.5 million in Series A funding to advance its cell therapy development platform. The round was led by Ahren Innovation Capital, with participation from Parkwalk, 24Haymarket, and the University of Bristol Enterprise Fund III. Mogrify's technology enables the transformation of any mature human cell type into another, offering potential breakthroughs in treating various diseases. The funding will support internal cell therapy programs, IP development, and team expansion.

Mogrify Secures €14.5 Million to Transform Cell Therapy Development

Mogrify is a biotechnology company based in Cambridge, UK, that specializes in developing life-saving cell therapies. Their proprietary direct cellular conversion technology allows them to transform any mature human cell type into another without using pluripotent stem cells or progenitor cells. This technology has the potential to revolutionize the treatment of various diseases, including musculoskeletal, autoimmune, cancer immunotherapy, ocular, and respiratory diseases.

Mogrify is a biotechnology company developing life-saving cell therapies by transforming human cell types.

6 years ago

Mogrify Secures €14.5 Million to Transform Cell Therapy Development

ProblemHealthcare

Solution

Covered on